



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification:</b> C12N 15/62, C07K 19/00, 14/82, 14/52, 14/78, 14/47, 16/18, 16/28, 16/44, C12N 1/21, 1/19, 5/10, A61K 38/17, 39/395, G01N 33/50 // (C12N 1/21, 1:19)	<b>A2</b>	<b>(11) International Publication Number:</b> WO 96/37621 <b>(43) International Publication Date:</b> 28 November 1996 (28.11.96)
<b>(21) International Application Number:</b> PCT/EP96/02230 <b>(22) International Filing Date:</b> 23 May 1996 (23.05.96)  <b>(30) Priority Data:</b> 95107914.4 23 May 1995 (23.05.95) EP (34) Countries for which the regional or international application was filed: DE et al.  <b>(71) Applicant (for all designated States except US):</b> MORPHOSYS GESELLSCHAFT FÜR PROTEINOPTIMIERUNG MBH [DE/DE]; Frankfurter Ring 193a, D-80807 Munich (DE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> PACK, Peter [DE/DE]; Franz-Wolter-Strasse 4/III, D-81925 Oberföhring (DE). HOESS, Adolf [DE/DE]; Wirtsbreite 21, D-83672 Wangau (DE).  <b>(74) Agent:</b> VOSSIUS AND PARTNER; P.O. Box 86 07 67, D- 81634 München (DE).		<b>(81) Designated States:</b> CA, CN, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished          upon receipt of that report.</i>
<b>(54) Title:</b> MULTIMERIC PROTEINS  <b>(57) Abstract</b> <p>The present invention relates to the construction and use of small multimerization devices, preferably of human origin, which self-assemble fused functional domains to multimeric and multifunctional complexes. Multimerization devices of this invention do not significantly interfere with secretion, expression yields and the independent folding of functional domains, which are attached via flexible but protease-resistant linkers. Modular gene cassettes encoding functional domains, linkers and multimerization domain can easily be combined to a cistron encoding the multimeric protein. Translation in a suitable host results in self-assembly to multimers larger than dimers. In cases, in which one or both functional domains are not expressible in sufficient yields or native fold in the same expression host, multimeric proteins can be produced, in which one or both functional domains or the multimerization device are produced separately by, e.g., in vitro translation, peptide synthesis and/or refolding and subsequently, e.g., chemically coupled to the remaining part of the multimeric protein.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## MULTIMERIC PROTEINS

### Field of the invention

The present invention relates to multimeric polypeptides which combine two or more functional domains in a structure which is capable of at least self-trimerization and which can be, for example, readily prepared in recombinant bacteria.

### Background of the Invention

Multivalency is a prerequisite for a variety of macromolecular interactions such as binding of antibodies or lectins to specific targets, ligand recognition, activation or inhibition of receptors as well as cell adhesion.

Carbohydrate binding by lectins such as conglutinin or IgE-binding protein requires multivalency (Hsu et al., 1992, J. Biol. Chem. 267, 14167-14174; Andersen et al., 1992, J. Struct. Biol. 109, 201-27). Compared to the monovalent ligand, the trimeric hepatic lectin (Verrey & Drickamer, 1993, Biochem. J. 292, 149-155) binds the trimeric ligand with an 100 to 1000-fold higher affinity (Lee et al, 1992, Arch. Biochem. Biophys. 299, 129-136).

Multimerization of cell surface receptors as well as of their ligands often define specificity and affinity. The multivalent interactions of CD2 receptors of T-cells with their ligands LFA-3 on the cognate partner are necessary for cell-cell contact and T-cell activation by stimulatory cells (Moingeon et al., 1989, Immunol. Rev. 111, 111-144).

Multivalent binding of heparin to fibroblast growth factor receptors induces receptor dimerization and results in mitogenic signal transduction (Pantoliano et al., 1994, *Biochemistry* 33, 10229-10248). The concentration-dependent dimerization of the cytokine IL-2 results in high-affinity binding to the IL-2 receptor and formation of the high-affinity complex regulating the subsequent signal transduction (Lothar et al., 1992, *Growth factors* 7, 117-129). Dimerization of CD4 induced by multivalent ligands is necessary to trigger the intracellular tyrosine kinase in T-cells (Langedijk et al., 1993, *Thromb.-Res.* 71, 47-60). The inhibition of IgE synthesis in allergic diseases requires the injection of at least bivalent anti-IgE immunoglobulins (Stämpfli et al., 1994, *Eur. J. Immunol.* 24, 2161-2167).

The enhancement of weak monovalent forces by multiplying the number of interactions is increasingly used for protein engineering and therapeutic applications. Synthetic peptides such as the bivalent hirudin-analogs "hirulogs" effectively inhibit clot-bound thrombin (Cannon et al., 1993, *Am. J. Cardiol.* 71, 778-782), a further optimization of related thrombin inhibitors being achieved by trivalency (Szewczuk et al., 1993, *Biochemistry* 32, 3396-3404). Multivalent glycopeptides inhibit binding of influenza viruses to their target cells (Unverzagt et al., 1994, *Carbohydr. Res.* 251, 285-301). The multivalent display of Tyr-Ile-Gly-Ser-Arg peptides strongly inhibits lung metastasis (Nomizu et al., 1993, *Cancer-Res.* 53, 3459-3461).

The synergistic gain in binding strength (functional affinity or avidity) through multivalent interactions is best characterized for binding of immunoglobulins to their specific antigens. The avidity effect is dependent on the affinity per binding site, flexibility and number of the

associated binding sites, number as well as distance of antigens within reach. As a rough estimate, the avidity is the product of affinities per monovalent binding event (Crothers & Metzger, 1972, Immunchemistry 9, 341).

Immunoglobulins such as monoclonal antibodies or heterologously expressed fragments belong to the most promising candidates for "targeted missiles" for screening and combat of tumours and any kind of pathogens in vivo (Colcher et al., 1990, J. Natl. Cancer Inst. 82, 1191-1197). The heterologous expression of so-called scFv antibody fragments, i. e. the variable domains of antibodies connected by a peptide linker (Bird et al., 1988, Science 242, 423; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85, 5879) combines several benefits.

The deletion of all constant immunoglobulin domains and the covalent linkage of the two variable domains (Fv) by a peptide linker (Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85, 5879; Bird et al., 1988, Science 242, 423) results in a stable, single-chain immunoglobulin of minimal size with a single, complete binding pocket. The small size of the single-chain Fv fragment (scFv) provides improved expression yields (Skerra & Plückthun, 1991, Protein Eng. 4, 971), proteolytic stability, tissue penetration (Colcher et al., 1990, J. Natl. Cancer Inst. 82, 1191) and decreased nonspecific interactions or immunogenicity compared to complete antibodies. An alternative design links the two variable domains via engineered disulfide bridges at the VL-VH interface (dsFv; Glockshuber et al., 1990, Biochemistry 29, 1362).

The disadvantage of these recombinant fragments, however, is their short in vivo half-life and their inability to form

bivalent complexes such as IgG or higher oligomers such as IgM, in which the binding pockets are able to reach two or more distant antigens simultaneously. In medical applications such as tumour targeting, however, the need for efficient tissue penetration and tight binding means that ideally, an immunoglobulin-based structure should combine relatively small size with high affinity/avidity and sufficient half-life (Thomas et al., 1989, Cancer Res. 49, 3290-3296). To regain the avidity of whole antibodies and prolonged half-life in vivo, several techniques were recently developed to access small dimeric and thus bivalent immunoglobulins, although each suffers from substantial disadvantages.

If the interdomain linker between VH and VL in single-chain Fv fragments (Bird et al., 1988, Science 242, 423-426) is sufficiently short, formation of monovalent scFv fragments is disfavoured, resulting in intermolecular association of VH and VL domains of two or more fragments to form scFv-dimers or higher oligomers. In the so-called diabody (Holliger et al., 1993, Proc. Natl. Acad. Sci. USA 90, 6444), the rigid structure and close proximity of the binding sites does not allow flexibility or binding to distant antigens (Perisic et al., 1994, Structure 2, 1217). The formation of stable dimers or higher oligomers is highly dependent on the VH-VL interface of a particular fragment, so that the conversion of an scFv to a diabody is not possible for every given sequence, and the degree of oligomerization is not controllable (Whitlow et al., 1994, Prot. Eng. 7, 1017-1026).

The direct in vitro linkage of two fragments with C-terminal cysteines by oxidation (Carter et al., 1992, Bio/Technology 10, 163) or through chemically attached spacers (Kipriyanov

et al, 1994, Mol. Immunol. 31, 1047-1085; Cook & Wood, 1994, J. Immunol. Meth. 171, 227-237) requires laborious isolation and refolding of purified material with poor yields of functional immunoglobulins. Additionally, since mixed disulphide bond formation cannot be excluded, aggregation to unspecified multimers may occur. Non-quantitative disulphide formation further diminishes the overall yield.

The use of amphipathic helices such as bundle helices or leucine zippers C-terminally fused to scFv fragments for dimerization in E.coli (Pack & Plückthun, 1992, Biochemistry 31, 1579-1584) provided access to dimeric, bivalent "mini-antibodies" (PCT/EP93/00082). The antibody fragments assemble exclusively to functional dimers in vivo and can be purified in high yields in a single affinity chromatography step (Pack et al., 1993, Bio/Technology 11, 1271-1277). Based on artificial bundle helices or non-human zipper-sequences, this design of the C-terminally fused "association domains" is potentially hampered by the immunogenicity of such sequences when applied as human therapeutics. Furthermore, bundle helices used as association domains are not able to tetramerize fused antibody fragments, since the association forces of single bundle helices are too weak to stabilize a tetramer (Pack & Plückthun, 1992, Biochemistry 31, 1579-1584).

Modified and therefore "artificial" zipper sequences fused to antibody fragments are able to bring about tetramerization, but incompatibilities of the modified zipper sequence with folding and secretion lead to a considerably diminished yield of functional tetrameric material (Pack et al., 1995, J. Mol. Biol. 246, 28-34) and

the complex incorporates only one type of function or functional domain, namely one scFv specificity.

Previously, the CH2-CH3-CH4 domains of immunoglobulin M heavy chains have also been used as carriers of a single functional domain, namely cell surface receptor ligands (PCT Application WO 92/03569). The resulting fusion proteins were expressed in certain mammalian cells as multimers.

For several reasons, the use of CH2-CH3-CH4 domains of immunoglobulin M heavy chains as multimerization devices suffers disadvantages.

First, the expression of such fusion proteins is restricted to certain expression hosts and cellular compartments. The specific glycosylation of constant domains of immunoglobulins is considered to be important for assembly, structure (Rademacher & Dwek, 1984, Prog. Immun. 5, 95-112) function (Burton, 1985, Mol. Immunol. 22, 161-206) and proteolytic stability (Leatherbarrow & Dwek, 1983, FEBS Lett. 164, 227-239) of immunoglobulin constant domains (Matsuda et al., 1990, Mol Immunol. 27, 571-579; Dorai et al., 1991, Hybridoma 10, 211-217). The change or absence of glycosylation patterns, for instance when using a murine instead of a human expression host, results in structural changes and loss of complement activation (Lund et al., 1990, Mol. Immunol. 27, 1145-1153). The correct human glycosylation pattern on immunoglobulin constant domains is only achievable in certain mammalian cell cultures, namely of human origin. A different glycosylation pattern by expression in other than human cells would also increase the immunogenicity in medical applications.



Furthermore, the use of antibody-based association domains of the proposed type suffers from the serious disadvantage of its enormous size of 343 residues per monomer corresponding to three distinct immunoglobulin folding domains (CH2, CH3, CH4) per monomeric fusion protein, with 6 disulphide bridges to be formed (Dorai & Gillies, 1989, Nucleic Acids Res. 17, 6412-6417) or 60 in the decameric, IgM-like complex. Constructs of this type are very unlikely to be producible in bacteria, and there is no report of the functional expression of an immunoglobulin having three correctly folded constant domains in bacteria.

It is well known that the folding efficiency and expression yield of recombinant soluble material depends on the length of the peptide chain, the number of distinct folding domains per chain as well as the number of cis-prolines and correct disulphide bridges to be formed (Jaenicke, 1987, Prog. Biophys. Mol. Biol. 49, 117-237). In procaryotic expression hosts like *E. coli*, the decrease in yield of larger recombinant proteins is even more pronounced than in yeast or cell culture. As one aspect of this observation, for instance, the proteolysis of recombinant and "foreign" proteins, especially in inter-domain sequences, increases with the number of folding domains per chain. The formation of correct disulphide bridges is a rate-limiting step of folding (Darby et al., 1992, J. Mol. Biol. 224, 905-911) and a prerequisite for a stable immunoglobulin fold (Creighton, 1988, BioEssays 8, 57-53; Skerra & Plückthun, 1991, Prot. Eng. 4, 971-979). In reducing environments such as cytoplasmic compartments, the formation of a disulphide bridge could not be shown (Glockshuber et al., 1992, Biochemistry 31, 1270-1279).

Self-assembly of relatively small fusion proteins, preferably without the need of glycosylation or disulphide bridges in vivo, however, would overcome these general problems mentioned above and result in novel, well expressed complexes.

Bacteria such E. coli provide a fast generation turnover, cheap fermentation, well established molecular biology protocols such as fast access to site-directed mutations. Recently, the display of recombinant proteins on bacteriophages (Greenwood et al., 1991, J. Mol. Biol. 220, 821-827) proved to be a unique tool in combination with random mutagenesis for the generation of large libraries and selection for the most valuable protein mutants. Only small and well expressed multimerization devices, preferably peptidic multimerization devices, would allow the efficient construction of multimeric proteins comprising library-derived recombinant proteins as functional domains.

A further limitation of WO 92/03569 is that it does not teach the preparation of multimers having two or more distinct functional domains per fusion protein. Indeed, WO92/03569 only provides for one example of a certain receptor ligand to be assembled in the multimeric proteins when fused to the CH2-CH3-CH4 domains of immunoglobulin M heavy chain and expressed in certain mammalian cells.

None of the prior art can provide substances combining the features of a relatively small size, low immunogenicity, and high yields of functional material with the self-assembly of stable multimeric complexes larger than dimers having at least two distinct functions.

The additional fusion of a second functional domain C-terminal to a peptidic, self-assembling multimerization device via a second flexible linker significantly broadens the range of applications of multimeric proteins. Self-assembly of a bifunctional fusion protein with the help of a "central" multimerization device (domain1-linker1-device-linker2-domain2) would result in a completely novel recombinant complex having two functions in preferably multiple copies in one complex.

A wide range of combinations of two different functional domains is now within reach. The assembly of two or more different antibody fragments to multivalent complexes with valencies equal to/or more than 3 per specificity as well as combination of unrelated functional domains such as enzymes, toxins, cytokines, kinases, phosphatases, lectins, peptide hormones, cell adhesion proteins such as integrins, metal-binding domains, peptidic vaccines, bioactive peptides or soluble cell surface proteins such as the CD molecules of leucocytes or parts thereof in one multimeric complex are of considerable interest for diagnostic and therapeutic applications.

The drawbacks associated with the prior art are overcome by the present invention, which is concerned with the preparation of multifunctional proteins which show the following features:

- (i) they can be prepared using standard recombinant micro-organisms, even though the molecular weight of the assembled protein exceeds that of proteins commonly expressed in bacteria,
- (ii) low immunogenicity in humans

(iii) exists as multimers of valency equal to/or greater than three

(iv) provide proteins carrying two or more functional domains in a single multimeric structure.

The present invention surprisingly provides small peptidic multimerization devices which support two functional domains, which may be distinct from each other, as N- and C-terminal fusions, with all three subunits folding into functional forms, and which can be produced without the need for refolding, for instance, in recombinant bacteria.

Within a multimeric protein of this invention, which can be encoded and translated as a single, contiguous monomeric polypeptide chain (domain1-linker1-multimerization device-linker2-domain2) with posttranslational self-assembly, such a peptidic multimerization device, however, must not greatly interfere with the folding and function of the N- and C-terminally fused domains, and it must self-associate in the steric context of the fused domains at both termini, even when the functional domains are of much larger size than the peptidic multimerization device. Peptidic multimerization devices of this invention provide for these properties.

It is well known in the art that not all kinds of polypeptides, i.e. functional domains can be produced in sufficient amounts and native fold in every expression host. This is due to differences in the folding and secretion environment, post-translational modifications such as glycosylation patterns and protease activities. However, the present invention also provides a solution to overcome these prior art problems. Namely, in these cases, a combined use of different expression hosts and/or in vitro synthesis has

to be used to create multimeric proteins with a central, peptidic multimerization device of this invention.

A certain functional domain, for instance, may require folding in the cytoplasm of a prokaryotic organism with subsequent refolding, but the second functional domain, with which the first functional domain should be combined does not properly fold in the cytoplasm of a prokaryotic organism but would need secretion in a mammalian host with subsequent glycosylation for a native fold.

Certain functional domains or parts thereof can be produced in vitro in cell-free translation systems (Nishimura et al., 1995, J. Fermentation and Bioengineering 80, 403-405) or as completely synthetic polypeptides (Fitzgerald et al., 1995, J. American Chemical Society 117, 11075-11080). Polypeptides with more than 100 amino acid residues, for instance, are currently synthesized using Fmoc chemistry on solid phase (Roggero et al., 1995, Molecular Immunology 32, 1301-1309).

Using in vitro synthesis, either a part or a complete multimeric protein of this invention can be synthesized and subsequently coupled, e.g. chemically or enzymatically in vitro (e.g. Harris et al., 1973, FEBS Lett. 29, 189-192) or by oxidation of additional, free cysteins (Carter et al., 1992, Bio/Technology 10, 163) to the remaining parts, which are separately produced in a different expression system or expression host. For example, the multimerization core may be cheaply synthesized in E. coli whereas the linkers and functional domains may be produced in different expression systems such as CHO cells, or bioactive peptides as functional domains by in vitro synthesis.

The benefits of a peptidic multimerization device of this invention can be demonstrated using the example of scFv fragments as N- and/or C-terminally fused functional domains. The multimeric protein combines greatly improved properties such as multivalent binding and bispecificity with prolonged half-live in vivo making it therefore particularly suitable for a variety of therapeutic applications. Fullfilling the needs of small size for tissue penetration, monomeric scFv fragments do not show avidity effects and are rapidly excreted, mainly via the kidneys. Their half-live  $t(1/2 \text{ alpha})$  is around 10-times shorter than that of a whole, bivalent antibody and 2 to 3-times shorter than that of a dimeric scFv fragment (Haunschild et al., 1995, Antibody, Immunoconjugates and Radiopharmaceuticals 8, 111-127), diminishing the chance to find the specific antigen and bind thereto. Multimeric scFv fragments are expected to have an considerably higher half-live and circulation time in vivo than monomeric or dimeric scFv fragments. Additionally, they can bind multivalently and can combine two specificities in one multimeric complex (the N-terminal scFv fragment as a functional domain may have a different specificity than the C-terminal functional domain).

The present invention provides for multimeric proteins comprising scFv fragments as N-and C-terminal functional domains which, for instance, combine two distinct scFv fragments (scFv1-linker1-device-linker2-scFv2)<sub>2</sub>. This entirely new design of multivalent & bispecific immunoglobulins is of enourmous interest for diagnostic and therapeutic purposes, since it enables, for instance, multivalent targeting of tumor tissue (specificity scFv1) and the recruitment of cytotoxic T-cells (specificity scFv2) to the tumor (Perez et al., 1985, Science 316, 354-356).

Furthermore, the present invention generally provides for heterotetramers that combine a variety of functions in one molecule. For example, the heterotetramerization may be a consequence of the association of structurally different multimerization devices. Alternatively, they may be the result of different functional domains fused N- or C-terminally (via the same or different linkers) to said devices as is detailed hereinbelow. Thus, the peptidic multimerization domain of this invention can be based on parts of natural proteins with the ability to heteromultimerize, such as the histone (H3/H4)<sub>2</sub> heterotetramer or the (TAF<sub>II</sub>42/TAF<sub>II</sub>62)<sub>2</sub> heterotetramer (Xie et al., 1996, Nature 380, 316-322), which both require less than 80 residues per subunit to heterotetramerize. Used as multimerization devices of this invention, 4 different functional domains (two domains N-terminally and two C-terminally fused via flexible linkers to the multimerization devices) can in principle self-assemble to a multimeric protein, in which 4 distinct functional domains appear twice.

It was surprisingly shown that the multimerization device fused to the linker and functional domain sequences as described in accordance with the present invention allows independent folding (Mack et al., Proc. Natl. Acad. Sci. USA 92, 7021-7025 (1995) and is essentially resistant to proteolytic attack which is not true for prior art constructs that employ a certain linker length. The linkers used in accordance with the present invention are preferably not larger than 15 amino acids.

The present invention also provides for a multimeric protein wherein the first functional domains are different for each

monomer and/or the second functional domains are different for each monomer. In this embodiment, the present invention also provides for the possibilities that the first and second functional domain(s) are the same or different.

Additionally, the present application provides for the possibility that the first and/or second functional domain(s) is/are fused to at least one further (functional) domain. Such constructs may advantageously comprise tags as functional domains at their N- or C-termini which may be used for purification purposes.

The present invention generally also provides for multimeric proteins of synthetic, semisynthetic or recombinant origin, wherein at appropriate locations cysteine residues are placed that are capable of forming cystine bridges within the multimerization device. Such cystine bridges confer a further enhanced stability on such multimeric proteins. The person skilled in the art is well aware of how such cysteines should be introduced into the multimerization devices and where they should be placed. For example, by appropriately manipulating the DNA sequence of the invention, certain amino acid codons may be changed into cysteine codons. Accordingly, thus modified DNA sequences are also comprised by the present invention.

The present invention also provides multimeric proteins and DNA sequences encoding the monomeric parts thereof, respectively, comprising appropriately designed additional cysteines as part of the multimerization device or the linker(s) to allow for intermolecular covalent linkage to additional functional domains, which are separately produced in vivo or in vitro and, for example, coupled to the



multimeric protein via oxidation of a free cystein to result in a covalent disulphide bridge.

The present invention also provides for multimerization devices, which are derived from libraries of randomized DNA sequences (EP 95 11 3021.0-2110 and EP-A 0 614 989). Such partially or fully randomized DNA sequences can be fused, for instance, to part of the gene III (gIII) of filamentous phage in an appropriate phagemid. After transformation of the phagemids into E. coli, gIII proteins can be produced as a fusion with a peptide encoded by one member of the library. After infection with helper phage, new phages are produced displaying the peptide of interest and incorporating the phagemid encoding for the displayed peptide. New multimerization devices can be identified by the interaction of the displayed peptide with a target peptide, which is, for instance, immobilized on a solid surface or fused to an infection mediating particle ("IMP").

### Detailed description of the invention

The object of this invention is a family of multimeric proteins which combine two or more functional domains. The multifunctional proteins of the present invention are based on small preferably peptidic multimerization devices which at least trimerize, and which can be N- and C-terminally fused to functional domains to form novel multimeric and multifunctional polypeptide complexes. The invention also provides DNA sequences, vectors, encoding said multifunctional proteins as well as methods for their production in vitro and in vivo. The invention further relates to gene cassettes as well as to pharmaceutical and diagnostical compositions comprising the protein of the invention.

Specifically, the present invention provides DNA sequences which encode:

- (i) a first functional domain,
- (ii) a first linker sequence,
- (iii) a multimerization device of preferably 30-80, and not more than 110 amino acids in length, which is capable of self-assembly to a trimer or higher order oligomer, and which is preferably of human composition,
- (iv) a second linker sequence, and
- (v) a second functional domain.

In this context, the term "functional domain" refers to an oligo- or polypeptide which has one or more functions, such as binding to a defined target substance, catalyzing reaction of a defined substrate, inhibiting the action of an enzyme, binding or blocking a receptor binding site or binding to a metal ion.

The items (i) to (v) mentioned above are preferably contiguous, and comprise a single open reading frame, allowing controllable expression of a single multi-functional protein from an appropriate vector. The illustration of the fusion principle of such a DNA sequence encoding a bifunctional, self-associating protein is shown in Fig. 1A.

The term 'linker sequence' is well known in the art. The linker used is not crucial for the present invention. Thus, in one construct, one and the same or different sequences can be used for the first and the second linker sequence.

A particular preferred embodiment of this invention is the use of a peptidic multimerization device based on a modified C-terminus of human p53 protein (Clore et al., 1994, Science 265, 386-391; Sakamoto et al., 1994, Proc. Natl. Acad. Sci. USA 91, 8974-8978; Soussi et al., 1990, Oncogene 5, 945-952).

The gene product of the human p53 tumor suppressor gene (Hollstein et al., 1991, Science 253, 49-53) contains distinct modular sequences for trans-activation (Unger et al., 1992, EMBO J. 11, 1383-1386), DNA-binding (Erlandson & Verdine, 1994, Chemistry & Biology 1, 79-84) and tetramerization (Clore et al., 1994, Science 265, 386-391; Sakamoto et al., Proc. Natl. Acad. Sci. USA 91, 8974-8978). The sequence responsible for tetramerization of the p53 (residues 319-360; Fig.2) can be separately expressed in E. coli (Studier et al., 1990, Methods Enzymol. 185, 60-64) resulting in a stable, symmetric 20 kD tetramer, containing helical as well as beta-strand secondary structures (Jeffrey et al., 1995, Science 267, 1498-1502).

The particular preferred p53-based multimerization device surprisingly allows self-assembly to a tetrameric complex with two different functional domains fused to its termini (Examples 1 - 3), where each of the fused functional domains can be more than eight times larger than the device (Example 2). Surprisingly and contrary to what the person skilled in the art would have expected, the human p53-based peptidic multimerization device has, in several cases, not greatly or significantly interfered with secretion, independent folding and function of the domains fused via flexible linkers, since the properties of both functional domains can be detected in the tetrameric complex directly isolated from the cell extract (Example 1). The small size and human origin of the p53 based peptidic multimerization device enables a significantly reduced immunogenicity in human compared to artificial or non-human self-associating sequences.

In a further preferred embodiment, the engineered peptidic multimerization device comprises self-associating, modified human platelet factor 4 (PF4; Zhang et al., 1994, Biochemistry 33, 8361-8366). PF4 (Fig. 4) is an abundant human serum protein of 101 residues secreted by platelets. It can be heterologously expressed in E. coli and self-assembles into tetramers with antiparallel beta-sheet like structures (Zhang et al., 1994, Biochemistry 33, 8361-8366).

The extracellular human protein TSP4, forming the basis of a further preferred embodiment of this invention, is a member of the thrombospondin family, which modulates the attachment of a variety of cells (Lawler et al., 1993, J. Cell. Biol. 120, 1059-1067). Residues 209 to 273 of human TSP4 (Fig. 21) show a high degree of homology to residues 20 to 83 of the

cartilage oligomeric protein (CMP or COMP). This homologous region is responsible for pentamerization of COMP and TSP4 (Efimov et al., 1994, FEBS letters 341, 54-58; Jenkins et al., 1990, J. Biol. Chem. 265, 19624-19631). Pentamerization of functional domains can be achieved by C- or N-terminal fusion to a TSP4-based peptidic multimerization device according to Examples 1 and 2.

In a preferred embodiment of the invention, the multimerization device is derived from a randomized DNA library in a suitable host, from which DNA members are identified by their ability to encode multimerizing peptides. Means and methods for such identification are well known to the person skilled in the art; see, e.g., EP 95 11 3021.0, or EP-A 0 614 989, which are incorporated herein by reference.

The present invention also provides for proteins, preferably fusion proteins, multimeric proteins consisting e.g. of such fusion proteins as well as methods of producing multimeric proteins of this invention. Such a method relates to the production of a protein comprising

- a) a first functional domain,
  - b) a first linker sequence,
  - c) a preferably peptidic multimerization device of not more than 110 and preferably 30-80 amino acid residues in length, which is capable of self-assembly to a trimer or higher order oligomer, and which is of predominantly human composition,
  - d) a second linker sequence, and
  - e) a second functional domain,
- wherein at least one of a) to e) is

- i) produced recombinantly, and, if all of a) to e) are produced recombinantly, at least two of the constituents are produced by different host cells; and/or
  - ii) produced synthetically; and/or
  - iii) produced semisynthetically; and/or
  - iv) produced by in-vitro translation; and
- wherein at least two of a) to e) are combined by enzymatic and/or chemical coupling thereby giving rise to the complete protein, and preferably to the complete multimeric protein.

For therapeutic purposes, it is often desirable that proteinaceous substances display the minimum possible immunogenicity. Accordingly, the present invention provides for multimeric polypeptides as described above in which at least one of said amino acid sequences, functional domains, or further (poly)peptides is of human origin. For example, the extracellular origin of the peptidic multimerization device based on parts of human PF4 or COMP is anticipated to provide for low immunogenicity in humans.

In a further preferred embodiment of this invention, the peptidic multimerization device comprises parts of the TATA Box binding protein associated factors (TAFIIs), preferably of human origin. *Drosophila* dTAFII42 and dTAFII62 are able to form hetero-tetrameric complexes resembling the (H3/H4)<sub>2</sub> hetero-tetrameric core of the chicken histone octamer (Xie et al., 1996, *Nature* 380, 316-322). The human homologues to dTAFII42 and dTAFII62 are hTAFII31 (Hisatake et al., 1995, *Proc. Natl. Acad. Sci. USA* 92, 8195-8199) and hTAFII80 (Hisatake et al., 1995, *Proc. Natl. Acad. Sci. USA* 92, 8195-8199; Weinzierl et al., 1993, *EMBO J.* 12, 5303-5309). Residues 13 to 87 of the human hTAFII31 and residues 10 to 82 of the human hTAFII80 can be used as a heterotetramerization device of this invention. Different

nomenclature may exist for identical hTAFII-proteins, such as hTAFII80 is also known as hTAFII70 (Hisatake et al., 1995, Proc. Natl. Acad. Sci. USA 92, 8195-8199).

In a further preferred embodiment of this invention, the peptidic multimerization device comprises parts of the histone H3 and H4 proteins, preferably residues 67 to 134 of human histone 3 (H3) and residues 29 to 95 of the human histone 4 (H4) (Fig 12a, b). The human H3 and H4 are highly homologous to the chicken H3 and H4, which resemble the structurally similar dTAFII42/dTAFII62 hetero-tetramer (Xie et al., 1996, Nature 380, 316-322).

In order to provide sufficient distance and flexibility between the peptidic multimerization device and fused functional domains, the peptidic multimerization device is linked via preferably hydrophilic, preferably flexible but protease-resistant polypeptide linkers to the functional domains. In a preferred embodiment of this invention, one or both of the linkers comprise protease-stable inter-domain linkers of human proteins (Argos, 1990, J. Mol. Biol. 211, 943-958), which provide sufficient flexibility and hydrophilicity. In a further preferred embodiment, the linker sequence is rich in the amino acid residues serine, threonine, glycine and proline, which provide an extended structure, rotational freedom, hydrophilicity as well as stability against proteases (Argos, 1990, J. Mol. Biol. 211, 943-958). In a particular preferred embodiment of the invention, the linker is a human antibody hinge sequence, particularly the TPLGTTTHT sequence derived from the upper hinge region of the human IgG3 antibody (Fig.4). In this context, the term antibody hinge sequence refers to an oligopeptide which links CH1 and CH2 domains and is responsible for flexibility, rotational freedom and long

range of the Fab arm to bind simultaneously to distant antigens (Dangl et al., 1988, EMBO J. 7, 1989-1994)

The present invention provides for many different types of functional domains to be multimerized. Thus, they may

- a) bind to a defined target substance, or
- b) catalyze reaction of a defined substrate, or
- c) inhibit the action of an enzyme, or
- d) bind or block a receptor binding side, or
- e) bind to a metal ion.

Preferred are also cases in which the sequences of at least one of the C- or N-terminal functional domains fused to the multimerization device comprise at least a part of a member of the immunoglobulin superfamily. In a particularly preferred embodiment, said functional domain is an antibody scFv fragment. This aspect of the invention provides multivalent antibody-like molecules, which can be of utility when simultaneous multivalent interaction with antigen is a prerequisite of recognition and stable binding to the specific antigen. This is the case, for instance, with carbohydrate antigens on a cell surface, against which individual antibody binding sites show poor affinity.

Also preferred are cases in which one or more functional domains fused to the peptidic multimerization device possess biological activity other than that of a member of the immunoglobulin superfamily. By way of example, the present invention provides for the targeted multimerization of enzymes, toxins, cytokines, kinases, phosphatases, lectins, peptide hormones, cell adhesion proteins such as integrins, metal-binding domains, peptidic vaccines, bioactive peptides or soluble cell surface proteins such as the CD molecules of leucocytes or parts thereof in one multimeric complex.



A preferred embodiment of this invention relates to constructs where the functional domains are bioactive peptides. Certain peptides derived from amphipathic loop structures of LPS-binding proteins (Hoess et al., 1993, EMBO J. 12, 3351-3356) are able to neutralize endotoxin. LPS often occurs in multimeric forms and it is therefore desirable to have access to multivalent forms of short (10-15 residues) LPS-binding peptides to ensure effective binding and neutralization of endotoxin. The present invention provides a method to express and multimerize several short peptides (Fig. 16) fused to the multimerization device. The peptides can be fused either to the N- or to the C-terminus (Fig. 17, 18) of the assembly domain via the peptide linkers. A fusion to both termini, e.g., to a p53 based multimerization device, results in a self-assembling octavalent complex of bioactive peptides. Alternatively, a combination with other functional domains can be achieved by their fusion to the opposite terminus of the peptidic multimerization device, resulting in a self-assembling complex displaying four bioactive peptides and four further functional domains.

The invention enables complex multimeric and multifunctional polypeptides to be constructed. By way of example, the second functional domain fused to the peptidic multimerization device can be taken from the list of cytokines, toxins, enzymes, kinases, phosphatases, lectins, peptide hormones, cell adhesion proteins such as integrins, metal-binding domains, purification devices, in particular peptides which are able to bind to an independent binding entity, peptidic vaccines, bioactive peptides, preferably of 5 to 15 amino acid residues, soluble cell surface proteins such as the CD molecules of leucocytes, DNA binding domains, transcription factors and growth factors or parts thereof.

A preferred embodiment of this invention is the use of decorsin as a functional domain. Decorsin is a 39 residue protein of the leech *Macrobdella decora* (Fig.13). It acts as a potent antagonist of the platelet glycoprotein IIb-IIIa (Seymour et al., 1990, J.Biol.Chem. 265, 10143-10147). According to example 2, the decorsin can be fused C- or N-terminally to the peptidic multimerization device (Fig. 3, 11, 12, 20, 22) and expressed in a suitable host. In arterial thrombotic diseases, the translated self-assembling multivalent decorsin complex may act as a powerful antithrombotic agent. Optionally, the N-terminal fusion of an anti-fibrin antibody fragment to a peptidic multimerization device, which carries a C-terminally fused decorsin, may result in targeting of the multimeric complex to blood clots.

The present invention provides for a standardized system of gene cassettes encoding functional domains, linkers and peptidic multimerization devices. Modular gene cassettes can easily be combined via unique restriction enzymes to a cistron (Fig. 1A). The cistron encodes for a self-associating protein, in which each monomeric subunit consists of an optional signal sequence for secretion, a first functional domain, a first linker sequence, an assembly domain of 30-110 amino acids in length, a second linker sequence and a second functional domain.

In a preferred embodiment said gene cassettes are directly cloned as a cistron into standard expression vectors enabling replication, under a regulatable promoter, translation and optionally secretion of the cistron-encoded protein. Host cells transformed with at least one vector or

vector cassette of the invention can be used for the preparation of said multimeric polypeptides.

In a further preferred embodiment said host cell is a mammalian, preferably human, yeast plant or bacterial preferably an E.coli cell.

The invention further provides for methods for the production of said multifunctional proteins, which methods comprise culturing a host cell of the invention in a suitable medium, and recovering said multimeric polypeptide produced by said host cell.

The invention further provides for methods for the separate production of parts of the multimeric protein such as the peptidic multimerization domain or/and one or both functional domains, and multimeric proteins and monomers thereof produced by said method which methods comprise at least one of peptide synthesis, in vitro translation, expression in hosts other than the hosts in which the remaining part of the multimeric protein is produced (e.g. by species, cell ionic or strain difference), and refolding with chemical coupling, e.g. subsequent or enzymatic, to the separately produced remaining part of the functional protein to result in a polypeptide that assembles to a multimeric protein of this invention.

The invention further provides for the introduction of appropriately placed additional cysteins to allow covalent intermolecular linkage of the multimerization device during or after self-assembly.

The invention further provides for the introduction of appropriately placed additional cysteins to allow linkage of

further functional domains, for example, by oxidation to intermolecular disulfide bridges.

In further preferred embodiments, the present invention provides for pharmaceutical and diagnostic compositions comprising the multimeric polypeptides described above, said pharmaceutical compositions optionally comprising a pharmaceutically acceptable carrier.

Finally, the invention provides for a kit comprising one or more vector cassettes useful in the preparation of said multimeric polypeptides.

The invention is now illustrated by reference to the following examples, which are provided for the purposes of illustration only and are not intended to limit the scope of the invention.

## EXAMPLES

**Example 1:** Formation of tetrameric complex incorporating four copies anti-Le<sup>Y</sup> scFv antibody fragments and four copies of a metal-binding domain by fusion of the two different functional domains to the 5'- and 3'-termini of a small tetramerization device based on human p53 via flexible linkers.

The peptidic multimerization device of this example is based on a modified C-terminus of human p53 (Soussi et al., 1990, Oncogene 5, 945-952; Clore et al., 1994, Science 265, 386-391; Fig. 2). A gene cassette (Fig. 3) synthesized by recursive PCR (Prodromou & Pearl, 1992, Protein Eng. 5, 827-829) encodes residues 319-360 of human p53 flanked by a SG-peptide incorporating an in-frame unique 5' restriction site (MroI) and a short C-terminal GGS GGAP linker incorporating an in-frame AscI restriction site at the 3'- terminus of the gene cassette encoding the peptidic multimerization device. The synthetic modular MroI-AscI gene cassette is 5' ligated to an EcoRI-MroI cassette encoding the human IgG3 upper hinge (Dangl et al., 1988, EMBO J. 7, 1989-1994; Fig. 4). The ligation product, a EcoRI-HindIII gene cassette encoding the tetramerization device, can be used for 5' (N-terminal) as well as 3' (C-terminal) fusions to genes encoding recombinant proteins or functional domains such as cytokines, toxins, immunoglobulins, enzymes, kinases, phosphatases, lectins, peptide hormones, cell adhesion proteins such as integrins, metal-binding domains, purification devices, in particular peptides which are able to bind to an independent binding entity, peptidic vaccines, bioactive peptides, preferably of 5 to 15 amino acid residues, soluble cell surface proteins such as the CD

molecules of leucocytes, DNA binding domains, transcription factors and growth factors (see further examples).

A cistron of the fusion protein of this example is constructed by the ligation of the following modular gene cassettes (5' -> 3') to a cistron und under a lac promoter/operator system in an appropriate E. coli expression plasmid (Fig. 6a, Ge et al., 1995, Antibody Engineering 2nd edition, C.A.K. Borrebaeck, ed. Oxford University Press, pp 229-266, Glockshuber et al., 1990, Biochemistry 29, 1362-1367; Skerra et al., 1991, Bio/Technology 9, 273-278):

- a XbaI-EcoRV cassette encoding an ompA signal sequence
- an EcoRV-EcoRI cassette encoding a LeY carbohydrate-binding scFv antibody fragment
- an EcoRI-MroI AscI gene cassette encoding a flexible upper hinge of human IgG3 (Fig. 4)
- a MroI-AscI encoding a peptidic multimerization device derived from the human IgG3 residues human p53 and a flexible GSGGAP linker incorporating the in-frame AscI-site (Fig. 3)
- a AscI-HindIII gene cassette encoding a functional domain for purification purposes which complexes metal ions.

The EcoRV-EcoRI cassette encoding the LeY carbohydrate-binding scFv antibody fragment MSL-5 was constructed by PCR amplification of the V-region cDNA of a hybridoma (Bradbury et al., 1995, Antibody Engineering 2nd edition, C.A.K. Borrebaeck, ed. Oxford University Press, pp 295-361) secreting anti-LeY antibodies. Appropriate PCR primers were used to introduce the EcoRV and EcoRI restriction sites and to assemble the scFv fragment with a 15 residue (Gly<sub>4</sub>Ser)<sub>3</sub> interdomain linker in a VL to VH polarity (Ge et al., 1995,

Antibody Engineering 2nd edition, C.A.K. Borrebaeck, ed. Oxford University Press, pp 229-266).

After transformation of the expression plasmid into an *E. coli* JM83 strain and induction of the lac promotor with IPTG at room temperature in shaking cultures, the translated fusion protein (MSL5-P53-His) is secreted into the periplasm and self-assembles into a tetrameric protein of this invention with four scFv fragments and four metal binding domains in one complex ("multibody"). In addition to applications such as incorporation of radioactive metal ions into a tetravalent anti-tumour complex, the metal binding function of the C-terminal domain can also be used for purification purposes. For example, the complex is isolated by immobilized metal ion chromatography IMAC (Lindner et al., 1992, Methods: a companion to Methods in Enzymology 4, 41-56; Fig. 5). The metal binding property of the tetrameric complex is demonstrated by the success of the purification procedure.

The peptidic multimerization device is compatible with secretion and folding of the anti Le<sup>Y</sup>-binding scFv fragment, so that no reduction in functional yields (compared to the monovalent scFv) is seen. Unexpectedly, the tetrameric and thus tetravalent fusion protein showed an improved expression behaviour compared to the monomeric scFv in this example, probably due to a reduced toxicity.

The tetramerization of the bifunctional fusion protein to a stable complex is shown by size exclusion at 0.5 micromolar concentration (Fig. 6B).

The characterization of binding kinetics to a LeY-coated biosensor surface was performed by surface plasmon resonance on a BIAcore (Pharmacia; Pack et al., 1995, J. Mol. Biol. 246, 28-34). All measurements were carried out in HBS buffer (Pharmacia) with a flow rate of 5  $\mu$ l/min at 25°C using one CM5 sensor cell of a biosensor machine (BIAcore, Pharmacia). LeY-BSA was covalently immobilized on the dextran matrix of a CM5 sensor chip using the standard amine immobilization procedure. Following activation of the chip surface with 50 mM N-hydroxysuccinimide and 200 mM N-(dimethylaminopropyl)-N'-ethylcarbodiimide, a LeY-BSA stock solution (155  $\mu$ g/ml) in PBS was diluted with an equal volume of sodium acetate (1 M, pH 3.0) and injected twice to give a high density surface (7000 RU) of immobilized LeY-BSA. For analysis of the MSL5 proteins, 20  $\mu$ l of each sample was injected at various concentrations (IgM: 0.3 - 14 nM, scFv: 0.37 - 3.75  $\mu$ M; dimeric mini-antibody: 0.12 - 2.4  $\mu$ M and multimeric MSL5-p53-His: 0.08 - 1.07  $\mu$ M). Dissociation was induced by injection of HBS buffer. After each measurement, the chip surface was regenerated with 10  $\mu$ l of 2 M guanidinium HCl diluted with an equal volume of HBS buffer.

The overlay plot of dissociation curves (Fig. 6c) reveals the second function of the tetrameric complex, namely the binding to a specific target, and illustrates the gain of avidity (functional affinity) by tetramerization of the scFv fragment antibody fragment. Compared to a monovalent scFv fragment and the dimeric construct scdHLX (PCT/EP93/00082), the tetrameric and thus tetravalent protein of this invention (MSL5-p53-His or "multibody") shows a significant enhancement of binding affinity to a surface covered with LeY-antigens. The gain in avidity can clearly be seen by the prolongation of the dissociation rate from milliseconds (scFv) to several minutes (MSL5-P53-His, Fig 6C).



The modular system of gene cassettes encoding the different association domains allows the facile generation of multivalent and bifunctional proteins with defined valency and steric properties. The multimeric protein of example 1 with four immunoglobulin binding sites can be an ideal design for applications where fast excretion and poor functional affinity of a monovalent fragment does not result in a significant, long-lasting enrichment at the target.

Furthermore, the dependence of the avidity (or "functional affinity") on the actual antigen density (Pack et al., J. Molecular Biology 246, 28-34) will allow a distinction between different tissues having different antigen densities. LeY is found in high densities on colon and breast cancer cells, but in low densities on a variety of normal cells (Sakamoto et al., 1986, Cancer Res. 46, 1553 - 1559). Since antibodies or immunotoxins with higher intrinsic affinity against LeY and related antigens also bind to cell surfaces with low antigen density, significant binding to normal tissues is observed (Trail et al., 1993, Science 261, 212 - 215). In principle, proteins of this invention with high avidity (by the multiplicity of binding events per molecule on a sufficient antigen density) but comparatively low intrinsic affinities (affinity per monovalent interaction, occurring also on low densities) are unable to bind to cells with low densities. Therefore, they will give rise to more selective targeting of cells with over-expressed antigen, which favor multivalent binding and will not cause unwanted side-effects by binding to normal cells with low antigen density.

**Example 2:** Formation of tetrameric complex incorporating four copies anti-phosphocholine scFv antibody fragments and

four copies of a human IL2 by fusion of the two different functional domains to the termini of a tetramerization device based on human p53 via flexible linkers.

According to example 1, a multimeric fusion protein is encoded by a cistron, which comprise modular gene cassettes encoding a signal sequence, a scFv antibody fragment as a N-terminal functional domain, a first flexible linker based on human IgG3 hinge, a tetramerization domain based on the human p53, a second linker and human IL2 as a C-terminal functional domain (Fig.8,9).

After translation and secretion in a suitable host according to example 1, the multimeric protein H11-p53-huIL2 is purified by the ability of its N-terminal functional domain to bind specifically to the antigen phosphocholine on a affinity column (Glockshuber et al., 1990, Biochemistry 29, 1362-1367). After this purification step, the function of its C-terminal domain, human IL2, was tested in a proliferation assay of cytotoxic T-lymphocytes (CTLL-A).

$3 \times 10^6$  cultivated CTLL-A cells, which can only grow in the presence of functional IL2, are extensively washed with IL2-free phosphate buffer (20 mM  $\text{NaH}_2\text{PO}_4$ , 100 mM NaCl, pH 7.4.) 2.5 % FCS, centrifuged and resuspended in IL2-free standard media with 10 % FCS. Aliquots of approximately  $1.5 \times 10^4$  cells in a 50 microliter volume are pipetted into each well of a 96-well microtiter plate. Increasing amounts of recombinant human IL2 for calibration (0.5 - 40 U; Sigma) as well as a dilution series of the phosphocholine-affinity purified H11-p53-huIL2 protein (10 ng - 150 ng) were co-incubated in duplicates for each concentration. After 24h at 37°C, the activity of active mitochondrial dehydrogenase (reflecting the number of living cells) is determined with MTT according

to Mossmann (1983, J. Immunological Methods 65, 55-57). The IL2 activity of the C-terminal functional domain of the multimeric protein (Fig. 9) is calculated using the calibration curve.

The proliferation of CTLL-A<sub>2</sub> cells in the presence of the multimeric protein, which was purified with the help of the anti-phosphocholine scFv as the N-terminal functional domain, clearly demonstrates the activity of the huIL2 as the C-terminal functional domain.

The surprising result, that the central multimerization domain allows independent native folding of the distinct domains with subsequent self-assembly, illustrates the potential of this invention.

The central (-linker1-device-linker2-) part of the multimeric protein serves, apart from its multimerization function, as a very long and protease-stable "spacer", allowing independent folding of the considerably (up to 6 times) larger fused domains. A conventional, extremely long linker of the same length as the central (-linker1-device-linker2-) part but without its secondary structure is probably much more protease-sensitive, as it is typical for unstructured peptides, which are well accessible for the catalytic pocket of proteases (Argos, 1990, J. Mol. Biol. 211, 943-958).

**Example 3:** Formation of tetrameric and bifunctional complex incorporating four copies of anti-ESL-1 scFv antibody fragments and four copies of a detection tag which in addition is used as a metal-binding domain by fusion of the two different functional domains to the termini of a small tetramerization device based on human p53 via flexible linkers.

The multimerization device of this example is described in Example 1.

A cistron of this fusion protein is constructed by the ligation of the following modular gene cassettes (5' -> 3') to a cistron under a lac promoter/operator system in an E. coli expression plasmid according to example 1:

- a XbaI-EcoRV cassette encoding an ompA signal sequence
- an EcoRV-EcoRI cassette encoding ESL-1 binding scFv antibody fragments
- an EcoRI-MroI AscI gene cassette encoding a flexible upper hinge of human IgG3 (Fig. 4)
- a MroI-AscI encoding a multimerization device derived from the human IgG3 residues human p53 and a flexible GGSGGAP linker incorporating the in-frame AscI-site (Fig. 3)
- a AscI-HindIII gene cassette encoding a functional domain for purification purposes which complexes metal ions and detection purposes of being specifically recognized by an antibody (Fig. 5).

The ESL-1 binding scFv antibodies were derived from a human combinatorial antibody library using phage display. After three rounds of panning 12 clones different in the sequence of the CDR3 heavy chain were selected and cloned via XbaI and EcoRI in to an appropriate expression vector (Fig. 6a). The human combinatorial antibody library construction and the panning of the ESL-1 binding antibodies is described in EP application 9511 3021.0-2110 "Protein libraries", the teachings of which are incorporated herein by reference. After transformation of the expression plasmids into an E. coli JM83 strain and induction of the lac promoter with IPTG at 30°C in shaking cultures for 4 h, the translated fusion

proteins were secreted into the periplasm as self-associating tetramers (scFv-linker1-device-linker2-purification domain) without the need of refolding or chemical cross-linking. For lysis, the cells (4 ml) were collected by centrifugation, re-dissolved in 800  $\mu$ l PBS pH 7.4 and sonicated for 90 sec. After another centrifugation step the supernatant was used for Western Blot analysis and binding experiments (ELISA). In parallel, conventional monomeric fusion proteins consisting of scFvs directly fused to the purification domain were prepared accordingly.

For characterizing the amounts of soluble secreted protein a Western Blot analysis was performed. 20  $\mu$ l of lysed bacterial supernatant was loaded on a 12.5 % polyacryl amide gel. After blotting the gel, the nitrocellulose filter was blocked with 3 % milk powder. In addition to using the metal binding function of the C-terminal domain for purification purposes the C-terminal domain was used as a detection tag specifically recognized by an anti-His antibody (Dianova).

It is demonstrated that, similar to the case with the LeY binding antibody (Example 1), the multimerization device is compatible with secretion and folding of the anti-ESL-1 binding scFv fragments, so that no significant reduction in functional yields is seen in this example as judged from the amounts of soluble protein detected in the Western Blot.

The characterization of binding activity to surface bound ESL-1 reveals the second function of the tetrameric complex, namely the binding to a specific target. For example, in an ELISA experiment, the antigen (ESL-1, 5 $\mu$ g/ml) was coated overnight at room temperature to a microtitre plate. After blocking with 3 % milk powder, the antigen was incubated for 2 h at room temperature with 200  $\mu$ l cell lysate either

expressing monomeric or tetrameric ESL-1 binding antibody fragments fused to the His-detection tag. After washing with PBS pH 7.4 (5x) the detection of ESL-1 binding was assayed by incubation with a first anti-His antibody (Dianova) and a second antibody linked to alkaline phosphatase and directed against the first antibody. Each measurement was performed in duplicate (Fig. 10).

The binding experiments of the ESL-1 binding antibody fragments reveal both functions of the tetrameric complex, namely the binding to a specific target and the detection of bound complexes, and illustrates the gain of avidity by tetramerization of the N-terminal functional domain, namely the scFv fragment antibody fragment. Compared to a monovalent scFv fragment the tetravalent and bifunctional proteins of this invention (each incorporating four copies of anti-ESL-1 scFv fragments) show a significant enhancement of measurable binding activity to a surface covered with ESL-1-antigens up to 10 or more times (9D5, 9D11, 9D31). In some cases, only binding of the multimeric and bifunctional complex of this invention is detectable (9D7, 9D9, 9D10) due to the synergistic effect of multiple binding sites (avidity-effect).

**Example 4: Hetero-tetramerization device based on parts of the human histones H3 and H4**

A synthetic gene containing the genetic information for the part of human histones H3 (Fig. 12a) and H4 (Fig. 12b) responsible for hetero-tetramerization are constructed with suitable restriction sites for 5' and 3' ligations according to Fig. 3, 20 and 22. The H3 and H4 based devices can be used for the hetero-tetramerization of multimeric proteins incorporating up to four different functional domains such

as cytokines, toxins, immunoglobulins, enzymes, kinases, phosphatases, lectins, peptide hormones, cell adhesion proteins such as integrins, metal-binding domains, purification devices, in particular peptides which are able to bind to an independent binding entity, peptidic vaccines, bioactive peptides, preferably of 5 to 15 amino acid residues, soluble cell surface proteins such as the CD molecules of leucocytes, DNA binding domains, transcription factors and growth factors. The hetero-tetramerization requires either co-expression of the two fusion proteins (domain1-linker1-device1 (e.g. H3) -linker2-device2 and domain3-linker3-device2 (e.g. H4) -linker4-device4) with the use of a suitable dicistronic expression system (Ge et al., 1995, Antibody Engineering 2nd edition, C.A.K. Borrebaeck, ed. Oxford University Press, pp 229-266) or separate expression with subsequent mixture and in vitro assembly. Instead of human histones H3 and H4, the hetero-tetramerization device can be based on sequences derived from the human hTAF<sub>II</sub>31 and hTAF<sub>II</sub>80 (Fig. 11 a,b).

**Example 5:** As a functional domain, the platelet aggregation inhibitor decorsin (Fig. 13) is either encoded by a N-terminal EcoRV-EcoRI (Fig. 14) or as C-terminal AscI-HindIII gene cassette (Fig. 15) and fused to a peptidic multimerization device of this invention via flexible linkers according to examples 1, 2 and 3.

**Example 6:** Formation of octavalent anti-LPS peptides (Fig. 16) by fusion to a tetramerization device based on the human p53.

The bioactive peptides can be fused as a gene cassette with suitable restriction sites either to the N-terminus (Fig.

17) or to the C-terminus (Fig. 18) of the assembly domain via the peptide linkers according to examples 1, 2 and 3.

**Example 7:** Tetramerization device based on the human serum protein PF4.

A synthetic gene containing the genetic information for PF4 (Fig. 19) and suitable restriction sites for 5' and 3' ligations (Fig. 20) can be used for the tetramerization of multimeric proteins incorporating functional domains such as cytokines, toxins, immunoglobulins, enzymes, kinases, phosphatases, lectins, peptide hormones, cell adhesion proteins such as integrins, metal-binding domains, purification devices, in particular peptides which are able to bind to an independent binding entity, peptidic vaccines, bioactive peptides, preferably of 5 to 15 amino acid residues, soluble cell surface proteins such as the CD molecules of leucocytes, DNA binding domains, transcription factors and growth factors according to Examples 1 to 3.

**Example 8:** Pentamerization device based on human TSP4 (Fig. 21), which can be used for the pentamerization of multimeric proteins incorporating functional domains such as cytokines, toxins, immunoglobulins, enzymes, kinases, phosphatases, lectins, peptide hormones, cell adhesion proteins such as integrins, metal-binding domains, purification devices, in particular peptides which are able to bind to an independent binding entity, peptidic vaccines, bioactive peptides, preferably of 5 to 15 amino acid residues, soluble cell surface proteins such as the CD molecules of leucocytes, DNA binding domains, transcription factors and growth factors according to Examples 1, 2 and 3.



## CLAIMS

1. A DNA sequence encoding:
  - a) a first functional domain,
  - b) a first linker sequence,
  - c) a multimerization device of not more than 110 and preferably 30-80 amino acids in length, which is capable of self-assembly to a trimer or higher order oligomer, and which is of mammalian and predominantly human composition,
  - d) a second linker sequence, and
  - e) a second functional domain.
2. The DNA sequence according to claim 1 in which said multimerization device comprises at least a part of the human p53 protein.
3. The DNA sequence according to claim 1 or 2 in which said peptidic multimerization device comprises amino acids 319 to 360 of the human protein p53.
4. The DNA sequence according to claim 1 in which said peptidic multimerization device comprises at least a part of the human PF4 protein.
5. The DNA sequence according to claim 1 in which said peptidic multimerization device comprises at least a part of the human TSP-4 protein.
6. The DNA sequence according to claim 1 in which said peptidic multimerization device comprises at least a part of the human COMP protein.

7. The DNA sequence according to claim 1 in which said peptidic multimerization device comprises at least a part of human thrombospondin.
8. The DNA sequence according to claim 1 in which said peptidic multimerization device comprises at least part of dTAF<sub>II</sub>42 or hTAF<sub>II</sub>31.
9. The DNA sequence according to claim 1 in which said peptidic multimerization device comprises at least part of dTAF<sub>II</sub>62 or hTAF<sub>II</sub>80.
10. The DNA sequence according to claim 1 in which said peptidic multimerization device comprises at least part of histone 3, preferably human histone 3.
11. The DNA sequence according to claim 1 in which said peptidic multimerization device comprises at least part of histone 4, preferably human histone 4.
12. The DNA sequence of any one of claims 1 to 11 encoding appropriately designed additional cysteines as part of the multimerization device to allow for intermolecular covalent linkage of the multimerization device during or after self-assembly.
13. The DNA sequence of any one of claims 1 to 12 encoding appropriately designed additional cysteines as part of the multimerization device or the linker(s) to allow for intermolecular covalent linkage to additional functional domains, which are separately produced in vivo or in vitro and coupled to the multimeric protein via oxidation of a free cysteine to result in a covalent disulphide bridge.

14. The DNA sequence according to any one of claims 1 to 14 wherein said linker sequences b) and d) are the same.
15. The DNA sequence according to any one of claims 1 to 14 wherein said linker sequences b) and d) are different.
16. The DNA sequence according to any of claims 1-15 in which said linkers are derived from the human inter-domain linking sequence.
17. The DNA sequence according to claim 16 in which said human inter-domain linking sequence comprises at least a part of a human antibody hinge sequence.
18. The DNA sequence according to claim 17 in which said human inter-domain linking sequence comprises at least a part of a human IgG3 hinge sequence.
19. The DNA sequence according to any of claims 1-18 in which one or both of said functional domains either:
  - a) bind to a defined target substance, or
  - b) catalyze reaction of a defined substrate, or
  - c) inhibit the action of an enzyme, or
  - d) bind or block a receptor binding side, or
  - e) bind to a metal ion.
20. The DNA sequence according to claim 19 in which one or both of said functional domains comprise at least a part of a member of the immunoglobulin super-family.
21. The DNA sequence according to claim 20 in which one or both of said functional domains is a single chain Fv-fragment.

22. The DNA sequence according to claim 20 in which one or both of said members of the immunoglobulin super-family binds to a carbohydrate target substance.
23. The DNA sequence according to claim 22 in which one or both of said members of the immunoglobulin super-family binds to Lewis Y-related carbohydrate structures.
24. The DNA sequence according to any one of claims 1 to 23 wherein said multimerization device is derived from a randomized DNA library in a suitable host, from which DNA members are identified by their ability to encode multimerizing peptides.
25. A vector, preferably an expression vector, comprising a DNA sequence according to any of claims 1-24.
26. The vector according to claim 24 comprising a first DNA sequence encoding a signal sequence for bacterial secretion and a second DNA sequence according to any of claims 1-24.
27. A cellular host comprising at least one vector according to claim 25 or 26.
28. The cellular host according to claim 27 which is mammalian, preferably human, yeast, plant, insect, preferably *Spodoptera frugiperda* or bacterial, preferably an *E. coli* cell.
29. A protein, preferably a fusion protein, comprising:
  - a) a first functional domain,
  - b) a first linker sequence,

- c) a preferably peptidic multimerization device of not more than 110 and preferably 30-80 amino acid residues in length, which is capable of self-assembly to a trimer or higher order oligomer, and which is of predominantly human composition,
  - d) a second linker sequence, and
  - e) a second functional domain.
30. A fusion protein encoded by the DNA sequence of any one of claims 1 to 24, the vector of any one of claims 25 to 26 or/and produced by the cellular host of claim 27 or 28.
31. A multimeric protein assembled from proteins and/or fusion proteins according to claim 29 or 30.
32. The multimeric protein of claim 31 which is a homomultimeric protein.
33. The multimeric protein of claim 31 which is a heteromultimeric protein.
34. A method of producing the fusion protein according to claim 29 or 30, said method comprising growing a cellular host according to claim 27 or 28 in an appropriate medium whereby said fusion protein is expressed, and isolating said fusion protein.
35. A method of producing a fusion protein according to claim 29 or 30, said method comprising growing a cellular host according to claim 27 or 28 in an appropriate medium whereby said protein is expressed, and secreted to the periplasm of said host, and

isolating said protein, preferably as a multimeric protein from said periplasm.


36. A method for producing a protein comprising
- a) a first functional domain,
  - b) a first linker sequence,
  - c) a multimerization device of not more than 110 and preferably 30-80 amino acids in length, which is capable of self-assembly to a trimer or higher order oligomer, and which is of mammalian and predominantly human composition,
  - d) a second linker sequence, and
  - e) a second functional domain,
- wherein at least one of a) to e) is
- i) produced recombinantly, and, if all of a) to e) are produced recombinantly, at least two of the constituents are produced by different host cells; and/or
  - ii) produced synthetically; and/or
  - iii) produced semisynthetically; and/or
  - iv) produced by in-vitro translation; and
- wherein at least two of a) to e) are combined by enzymatic and/or chemical coupling thereby giving rise to the complete protein and preferably to the complete multimeric protein.
37. A method of producing a multimeric protein, said method comprising associating at least three proteins according to claim 36, said method giving rise either to homomultimeric or heteromultimeric proteins.
38. A diagnostic composition comprising at least a fusion protein according to claim 29 or 30, and/or a

multimeric protein according to any one of claims 31 to 33.

39. A pharmaceutical composition comprising at least a fusion protein protein according to claim 29 or 30, and/or a multimeric protein according to any one of claims 31 to 33 optionally in combination with a pharmaceutically acceptable carrier.
40. A gene cassette comprising at least one DNA sequence according to any one of claims 1 to 24.
41. A kit comprising at least one gene cassette according to claim 40.


1/18

Fig.1A Modular cistron encoding a bifunctional, self-assembling fusion protein





2/18

**Fig. 1B.** schematic illustration of the self-assembly process

SUBSTITUTE SHEET (RULE 26)

3/18

Fig.2: protein sequence of the tetramerization domain of human p53

```

      10      20      30      40
KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG G.

```

Fig.3 synthetic MroI-AscI gene cassette encoding for a multimerization device based on human p53 (note: the cleavage sequence of restriction sites in this and all following figures is simplified for illustration purposes, the synthetic inserts are sticky-ended with appropriate overhangs).

```

MroI
S G K P L D G E Y F T L Q I R G R E
5' TCC GGA AAA CCA CTG GAT GGA GAA TAT TTC ACC CTT CAG ATC CGT GGG CGT GAG
   9      18      27      36      45      54
3' AGG CCT TTT GGT GAC CTA CCT CTT ATA AAG TGG GAA GTC TAG GCA CCC GCA CTC

```

```

R F E M F R E L N E A L E L K D A Q
CGC TTC GAG ATG TTC CGA GAG CTG AAT GAG GCC TTG GAA CTC AAG GAT GCC CAG
   63      72      81      90      99      108
GCG AAG CTC TAC AAG GCT CTC GAC TTA CTC CGG AAC CTT GAG TTC CTA CGG GTC

```

```

                          AscI
A G K E P G G S G G A P
GCT GGG AAG GAG CCA GGG GGG AGC GGA GGC GCG CCG 3'
   117      126      135      144
CGA CCC TTC CTC GGT CCC CCC TCG CCT CCG CGC GGC 5'

```

SUBSTITUTE SHEET (RULE 26)

4/18

Fig.4: synthetic EcoRI-MroI gene cassette encoding a N-terminal flexible linker of human origin based on the upper hinge of human IgG3 (huIgG3) as a flexible, protease-stable peptide linker between a N-terminal functional domain and a peptidic multimerization device of this invention.


EcoRI										MroI				
E	F	T	P	L	G	D	T	T	H	T	S	G		
5'	GAA	TTC	ACC	CCG	CTG	GGT	GAC	ACC	ACC	CAC	ACC	TCC	GGA	3'
			9			18			27			36		
3'	CTT	AAG	TGG	GGC	GAC	CCA	CTG	TGG	TGG	GTG	TGG	AGG	CCT	5'

Fig.5: AscI-HindIII gene cassette encoding a C-terminal metal binding domain

AscI								Hind III					
A	P	H	H	H	H	H	H	*	*				
5'	GCG	CCG	CAC	CAC	CAC	CAC	CAC	TGA	TAA	GCT	T	3'	
			9			18			27				
3'	CGC	GGC	GTG	GTG	GTG	GTG	GTG	CAC	ACT	ATT	CGA	A	5


5/18

**Fig.6A.** pACK phagemid vector for expression of the tetrameric and bifunctional fusion protein MSL5-p53-His in *E. coli*.




6/18

Fig. 6B.: Size exclusion chromatography of MSL-5 antibody constructs (•) (monomeric scFv, dimeric "miniantibody" and tetrameric/bifunctional MSL5-p53-His ("multibody") at 0.5 micromolar concentrations). The column (Superose 12, Pharmacia) was calibrated with standard proteins in HBS (o) (cytochrome c: 12,4 kD; carbonic anhydrase: 29 kD; albumin: 66 kD; alcohol dehydrogenase: 150 kD;  $\beta$ -amylase: 200 kD).



7/18

Fig 6C.: BIAcore overlay plot of individual dissociation curves of the MSL-5 IgM (14 nM) (A), the tetrameric and bifunctional protein MSL5-p53-His (1.07  $\mu$ M) (B), the dimeric miniantibody (2.4  $\mu$ M) (C) and monomeric scFv fragment (0.67  $\mu$ M) (D).



8/18

Fig.7 : Protein sequence of human Interleukin-2 (huIL2)

10	20	30	40	50	60
APTSSSTKKT QLQLEHLLLD LQMILNGINN YKNPKLTRML TFKFYMPKKA TELKHLQCLE					
70	80	90	100	110	120
EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR					
130					
WITFCQSIIS TLTDV*					

9/18

Fig. 8.: Synthetic AscI-HindIII cassette encoding human IL2 as a C-terminal functional domain of this invention.

AscI

G A P A P T S S S T K K T Q L Q L E

5' GGC GCG CCG GCA CCT ACT TCA AGT TCT ACA AAG AAA ACA CAG CTA CAA CTG GAG

9 18 27 36 45 54

3' CCG CGC GGC CGT GGA TGA AGT TCA AGA TGT TTC TTT TGT GTC GAT GTT GAC CTC

H L L L D L Q M I L N G I N N Y K N

CAT TTA CTG CTG GAT TTA CAG ATG ATT TTG AAT GGA ATT AAT AAT TAC AAG AAT

63 72 81 90 99 108

GTA AAT GAC GAC CTA AAT GTC TAC TAA AAC TTA CCT TAA TTA ATG TTC TTA

P K L T R M L T F K F Y M P K K A T

CCC AAA CTC ACC AGG ATG CTC ACA TTT AAG TTT TAC ATG CCC AAG AAG GCC ACA

117 126 135 144 153 162

GGG TTT GAG TGG TCC TAC GAG TGT AAA TTC AAA ATG TAC GGG TTC TTC CGG TGT

E L K H L Q C L E E E L K P L E E V

GAA CTG AAA CAT CTT CAG TGT CTA GAA GAA GAA CTC AAA CCT CTG GAG GAA GTG

171 180 189 198 207 216

CTT GAC TTT GTA GAA GTC ACA GAT CTT CTT CTT GAG TTT GGA GAC CTC CTT CAC

L N L A Q S K N F H L R P R D L I S

CTA AAT TTA GCT CAA AGC AAA AAC TTT CAC TTA AGA CCC AGG GAC TTA ATC AGC

225 234 243 252 261 270

GAT TTA AAT CGA GTT TCG TTT TTG AAA GTG AAT TCT GGG TCC CTG AAT TAG TCG

N I N V I V L E L K G S E T T F M C

AAT ATC AAC GTA ATA GTT CTG GAA CTA AAG GGA TCT GAA ACA ACA TTC ATG TGT

279 288 297 306 315 324

TTA TAG TTG CAT TAT CAA GAC CTT GAT TTC CCT AGA CTT TGT TGT AAG TAC ACA

E Y A D E T A T I V E F L N R W I T

GAA TAT GCT GAT GAG ACA GCA ACC ATT GTA GAA TTT CTG AAC AGA TGG ATT ACC

333 342 351 360 369 378

CTT ATA CGA CTA CTC TGT CGT TGG TAA CAT CTT AAA GAC TTG TCT ACC TAA TGG

HindIII

F C Q S I I S T L T D V \* \*

TTT TGT CAA AGC ATC ATC TCA ACA CTG ACT GAC GTC TGA TAA GCT T-3'


387 396 405 414

AAA ACA GTT TCG TAG TAG AGT TGT GAC TGA CTG CAG ACT ATT CGA A-5'



10/18


Fig. 9. CTLL-A proliferation assay for the determination of IL2-activity of the bifunctional and multimeric protein H11-p53-huIL2.



SUBSTITUTE SHEET (RULE 26)

11/18

Fig. 10. Anti-ESL-1 ELISA: measurable affinity (avidity) of 12 library-derived tetrameric and bifunctional scFv-p53-His proteins to ESL-1 in comparison to the monomeric scFv-His formats. Binding proteins are detected with antibodies against the C-terminal functional domain, the polyhistidine metal binding site.



12/18

Fig. 11a.: Residues 13 to 87 of the human hTAF<sub>II</sub>31 as a hetero-tetramerization device of this invention

P K D A Q M M A Q I L K D M G I T E Y E P R V I N Q M L E F  
A F R Y V T T I L D D A K I Y S S H A K K A T V D A D D V R  
L A I Q C R A D Q S F T S P P.

Fig. 11b.: Residues 10 to 82 of the human hTAF<sub>II</sub>80 as a hetero-tetramerization device of this invention

S N T V L P S E S M K V V A E S M G I A Q I Q E E T C Q L L  
T D E V S Y R I K E I A Q D A L K F M H M G K R Q K L T T S  
D I D Y A L K L K N V E P

Fig. 12a.: residues 67 to 134 of the human histone 3 (H3) as a hetero-tetramerization device of this invention

P F Q R L M R E I A Q D F K T D L R F Q S S A V A L Q E A C  
E S Y L V G L F E D T N L C V I H A K R V T I M P K D I Q L  
A R R I R G

Fig 12b.: Residues 29 to 95 of the human histone 4 (H4) as a hetero-tetramerization device of this invention

G I T K P A I R R L A R R G G V K R I S G L I Y E E T R G V  
L K V F L E N V I R D A V T Y T E H A K R K T V T A M D V V  
Y A L K R Q G

13/18

Fig.13: Protein sequence of the platelet aggregation inhibitor decorsin as a functional domain of this invention.

1	11	21	31
APRLPQCOGD	DQEKCLCNKD	ECPPGQCRFP	RGDADPYCE

14/18

Fig. 14.: Synthetic EcoRV-EcoRI cassette encoding the platelet aggregation inhibitor decorsin as a N-terminal functional domain of this invention.

## EcoRV

```

D I A P R L P Q C Q G D D Q E K C L
GAT ATC GCT CCG CGT CTG CCG CAG TGC CAG GGT GAC GAC CAG GAA AAA TGC CTG
          9          18          27          36          45          54
CTA TAG CGA GGC GCA GAC GGC GTC ACG GTC CCA CTG CTG GTC CTT TTT ACG GAC

```

```

C N K D E C P P G Q C R F P R G D A
TGC AAC AAA GAC GAA TGC CCG CCG GGT CAG TGC CGT TTC CCG CGT GGT GAC GCT
          63          72          81          90          99          108
ACG TTG TTT CTG CTT ACG GGC GGC CCA GTC ACG GCA AAG GGC GCA CCA CTG CGA

```

## EcoRI

```

D P Y C E F
GAC CCG TAC TGC GAA TTC 3'
          117          126
CTG GGC ATG ACG CTT AAG 5'

```

Fig.15: Synthetic AscI-HindIII cassette encoding the platelet aggregation inhibitor decorsin as a C-terminal functional domain of this invention.

## AscI

```

A P A P R L P Q C Q G D D Q E K C L
GCG CCG GCT CCG CGT CTG CCG CAG TGC CAG GGT GAC GAC CAG GAA AAA TGC CTG
          12          21          30          39          48          57
CGC GGC CGA GGC GCA GAC GGC GTC ACG GTC CCA CTG CTG GTC CTT TTT ACG GAC

```

```

C N K D E C P P G Q C R F P R G D A
TGC AAC AAA GAC GAA TGC CCG CCG GGT CAG TGC CGT TTC CCG CGT GGT GAC GCT
          66          75          84          93          102          111
ACG TTG TTT CTG CTT ACG GGC GGC CCA GTC ACG GCA AAG GGC GCA CCA CTG CGA

```

## HindIII

```

D P Y C E * *
GAC CCG TAC TGC GAA TGA TAA GCT T 3'
          120          129
CTG GGC ATG ACG CTT ACT ATT CGA A 5'

```

15/18

Fig.16: Peptide sequence of an endotoxin-neutralizing peptide as a functional domain of this invention

```

      1           11
      RWKVRKSFFKL Q

```

Fig.17: Synthetic EcoRV-EcoRI cassette encoding an endotoxin-neutralizing peptide as a N-terminal functional domain of this invention.

```

EcoRV                                     EcoRI
  I   M   R   W   K   V   R   K   S   F   F   K   L   Q   E   F
5' ATC ATG CGT TGG AAA GTT CGT AAA TCT TTC TTC AAA CTG CAG GAA TTC 3'
      9           18           27           36           45
3' TAG TAC GCA ACC TTT CAA GCA TTT AGA AAG AAG TTT GAC GTC CTT AAG 5'

```

Fig.18: Synthetic AscI-HindIII cassette encoding an endotoxin-neutralizing peptide as a C-terminal functional domain of this invention.

```

AscI                                     HindIII
  A   P   R   W   K   V   R   K   S   F   F   K   L   Q   *   *
5' GCG CCG CGT TGG AAA GTT CGT AAA TCT TTC TTC AAA CTG CAG TGA TAAGCTT 3'
      9           18           27           36           45
3' CGC GGC GCA ACC TTT CAA GCA TTT AGA AAG AAG TTT GAC GTC ACT ATTCGAA 5'

```

Fig.19: protein sequence of human plasma protein PF4

```

1 mssaagfcas rpglflflgll llplvvafas aeaeedgdlq
41 clcvktttsqv rprhitslev ikagphcpta qliatlkngr
81 kicldlqapl ykkiikkllle s

```

16/18

Fig. 20: Synthetic MroI-AscI-HindIII gene cassette encoding a tetramerization device of this invention based on the human plasma protein PF4.

MroI

S G M S S A A G F C A S R P G L L F

5' TCC GGA ATG TCT TCT GCT GCT GGT TTC TGC GCT TCT CGT CCG GGT CTG CTG TTC

9 18 27 36 45 54

3' AGG CCT TAC AGA AGA CGA CGA CCA AAG ACG CGA AGA GCA GGC CCA GAC GAC AAG

L G L L L L P L V V A F A S A E A E

CTG GGT CTG CTG CTG CTG CCG CTG GTT GTT GCT TTC GCT TCT GCT GAA GCT GAA

63 72 81 90 99 108

GAC CCA GAC GAC GAC GAC GGC GAC CAA CAA CGA AAG CGA AGA CGA CTT CGA CTT

E D G D L Q C L C V K T T S Q V R P

GAA GAC GGT GAC CTG CAG TGC CTG TGC GTT AAA ACC ACC TCT CAG GTT CGT CCG

117 126 135 144 153 162

CTT CTG CCA CTG GAC GTC ACG GAC ACG CAA TTT TGG TGG AGA GTC CAA GCA GGC

R H I T S L E V I K A G P H C P T A

CGT CAC ATC ACC TCT CTG GAA GTT ATC AAA GCT GGT CCG CAC TGC CCG ACC GCT

171 180 189 198 207 216

GCA GTG TAG TGG AGA GAC CTT CAA TAG TTT CGA CCA GGC GTG ACG GGC TGG CGA

Q L I A T L K N G R K I C L D L Q A

CAG CTG ATC GCT ACC CTG AAA AAC GGT CGT AAA ATC TGC CTG GAC CTG CAG GCT

225 234 243 252 261 270

GTC GAC TAG CGA TGG GAC TTT TTG CCA GCA TTT TAG ACG GAC CTG GAC GTC CGA

P L Y K K I I K K L L E S G G S G G

CCG CTG TAC AAA AAA ATC ATC AAA AAA CTG CTG GAA TCT GGG GGG AGC GGA GGC

279 288 297 306 315 324

GGC GAC ATG TTT TTT TAG TAG TTT TTT GAC GAC CTT AGA CCC CCC TCG CCT CCG

AscI

A P

GCG CCG 3'

333

CGC GGC 5'

17/18

Fig. 21: Protein sequence of residues 209 to 273 of the human TSP4

209 EP LAATGTGDFN RQFLGQMTQL NQLLGEVKDL LRQQVKETSF

251 LRNTIAECQA CGPLKFQSPT PST



18/18

Fig. 22: Synthetic MroI-AscI gene cassette encoding a pentamerization device of this invention based on residues 209 to 273 of the human TSP4.

## MroI

S G E P L A A T G T G D F N R Q F L  
 5' TCC GGA GAA CCG CTG GCG GCG ACC GGC ACC GGC GAT TTT AAC CGT CAG TTT CTG  
                   9                  18                  27                  36                  45                  54  
 3' AGG CCT CTT GGC GAC CGC CGC TGG CCG TGG CCG CTA AAA TTG GCA GTC AAA GAC

G Q M T Q L N Q L L G E V K D L L R  
 GGC CAG ATG ACC CAG CTG AAC CAG CTG CTG GGC GAA GTG AAA GAT CTG CTG CGT  
                   63                  72                  81                  90                  99                  108  
 CCG GTC TAC TGG GTC GAC TTG GTC GAC GAC CCG CTT CAC TTT CTA GAC GAC GCA

Q Q V K E T S F L R N T I A E C Q A  
 CAG CAG GTG AAA GAA ACC AGC TTT CTG CGT AAC ACC ATT GCG GAA TGC CAG GCG  
                   117                  126                  135                  144                  153                  162  
 GTC GTC CAC TTT CTT TGG TCG AAA GAC GCA TTG TGG TAA CGC CTT ACG GTC CGC

C G P L K F Q S P T P S T G G S G G  
 TGC GGC CCG CTG AAA TTT CAG AGC CCG ACC CCG AGC ACC GGG GGG AGC GGA GGC  
                   171                  180                  189                  198                  207                  216  
 ACG CCG GGC GAC TTT AAA GTC TCG GGC TGG GGC TCG TGG CCC CCC TCG CCT CCG

## AscI

A P  
 GCG CCG 3'  
                   222  
 CGC GGC 5'





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> C12N 15/62, C07K 19/00, 14/82, 14/52, 14/78, 14/47, 16/18, 16/28, 16/44, C12N 1/21, 1/19, 5/10, A61K 38/17, 39/395. G01N 33/50 // (C12N 1/21, C12R 1:19)	<b>A3</b>	<b>(11) International Publication Number:</b> WO 96/37621 <b>(43) International Publication Date:</b> 28 November 1996 (28.11.96)
<b>(21) International Application Number:</b> PCT/EP96/02230 <b>(22) International Filing Date:</b> 23 May 1996 (23.05.96)  <b>(30) Priority Data:</b> 95107914.4 23 May 1995 (23.05.95) EP <b>(34) Countries for which the regional or international application was filed:</b> DE et al.  <b>(71) Applicant (for all designated States except US):</b> MORPHOSYS GESELLSCHAFT FÜR PROTEINOPTIMIERUNG MBH [DE/DE]; Frankfurter Ring 193a, D-80807 Munich (DE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> PACK, Peter [DE/DE]; Franz-Wolter-Strasse 4/III, D-81925 Oberföhring (DE). HOESS, Adolf [DE/DE]; Wirtsbreite 21, D-83672 Wangau (DE).  <b>(74) Agent:</b> VOSSIUS AND PARTNER; P.O. Box 86 07 67, D-81634 München (DE).	<b>(81) Designated States:</b> CA, CN, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the International search report:</b> 3 January 1997 (03.01.97)	
<b>(54) Title:</b> MULTIMERIC PROTEINS  <b>(57) Abstract</b>  The present invention relates to the construction and use of small multimerization devices, preferably of human origin, which self-assemble fused functional domains to multimeric and multifunctional complexes. Multimerization devices of this invention do not significantly interfere with secretion, expression yields and the independent folding of functional domains, which are attached via flexible but protease-resistant linkers. Modular gene cassettes encoding functional domains, linkers and multimerization domain can easily be combined to a cistron encoding the multimeric protein. Translation in a suitable host results in self-assembly to multimers larger than dimers. In cases, in which one or both functional domains are not expressible in sufficient yields or native fold in the same expression host, multimeric proteins can be produced, in which one or both functional domains or the multimerization device are produced separately by, e.g., in vitro translation, peptide synthesis and/or refolding and subsequently, e.g., chemically coupled to the remaining part of the multimeric protein.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## INTERNATIONAL SEARCH REPORT

Int ional Application No

PCT/EP 96/02230

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 6	C12N15/62	C07K19/00	C07K14/82	C07K14/52	C07K14/78
	C07K14/47	C07K16/18	C07K16/44	C07K16/28	C12N1/21
	C12N1/19	C12N5/10	A61K38/17	A61K39/395	G01N33/50
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols)					
IPC 6	C12N	C07K	A61K	G01N	
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the relevant passages				Relevant to claim No.
P,X	WO,A,96 13583 (MORPHOSYS PROTEINOPTIMIERUNG ;PACK PETER (DE); LUPAS ANDREI (DE)) 9 May 1996 see figure 2				1,25-37
X	J IMMUNOL METHODS, JAN 27 1995, 178 (2) P201-9, NETHERLANDS, XP000608189 DUBEL S ET AL: "Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv)." see the whole document				1,25-41
-/-					
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.					
* Special categories of cited documents : 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. '&' document member of the same patent family					
Date of the actual completion of the international search			Date of mailing of the international search report		
5 November 1996			15. 11. 96		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016			Authorized officer  Espen, J		

Form PCT/ISA/210 (second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/02230

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 //((C12N1/21,C12R1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	HUM ANTIBODIES HYBRIDOMAS, 1995, 6 (3) P93-101, UNITED STATES, XP000607119 KIPRIYANOV SM ET AL: "Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen." see figure 5	1,25-41
Y	WO,A,93 15210 (MERCK PATENT GMBH) 5 August 1993 cited in the application see page 10 - page 13; examples 1-4 --- -/--	1-3, 12-16, 25-41

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

15. 11. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

## INTERNATIONAL SEARCH REPORT

Int: mal Application No

PCT/EP 96/02230

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J MOL BIOL, FEB 10 1995, 246 (1) P28-34, ENGLAND, XP000607470 PACK P ET AL: "Tetravalent miniantibodies with high avidity assembling in Escherichia coli." see the whole document ---	1-7, 12-16, 25-41
Y	FEBS LETTERS, vol. 341, 1994, AMSTERDAM NL, pages 54-58, XP002017642 EFIMOV VP ET AL: "The thrombospondin-like chains of cartilage oligomeric matrix protein are assembled by a five-stranded alpha-helical bundle between residues 20 and 83" cited in the application see the whole document ---	1-7, 12-16, 25-41
Y	BIOCHEMISTRY, vol. 33, 1994, EASTON, PA US, pages 8361-8366, XP002017643 LAI CK ET AK: "Crystal structure of recombinant human platelet factor 4" cited in the application see page 4 ---	1-7, 12-16, 25-41
Y	PROC NATL ACAD SCI U S A, SEP 13 1994, 91 (19) P8974-8, UNITED STATES, XP000608191 SAKAMOTO H ET AL: "Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution." cited in the application see abstract ---	1-3, 12-16, 25-41
Y	SCIENCE, MAR 10 1995, 267 (5203) P1498-502, UNITED STATES, XP000608194 JEFFREY PD ET AL: "Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms." cited in the application see abstract -----	1-3, 12-16, 25-41

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/EP 96/02230

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9613583	09-05-96	NONE	
WO-A-9315210	05-08-93	AU-A- 3410093	01-09-93
		CA-A- 2128511	05-08-93
		CZ-A- 9401757	15-12-94
		EP-A- 0654085	24-05-95
		HU-A- 68798	28-07-95
		JP-T- 7503366	13-04-95
		NO-A- 942750	13-09-94